Vaccine, varicella-zoster


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intramuscular, Subcutaneous
Active immunisation against varicella infection
Adult: Each 0.5 mL contains live, attenuated varicella-zoster virus (VZV) Oka/Merck strain ≥103.3 plaque-forming units (PFU), or ≥1,350 PFU: 0.5 mL for 2 doses via deep SC or IM inj, doses are given 4-8 weeks apart.
Child: 9 months to 12 years (or 1-12 years, based on product used) 0.5 mL for 2 doses via deep SC or IM inj; the 2nd dose is to be given after an interval of at least 3 months (or 6 months based on national recommendations); ≥13 years Same as adult dose.

Subcutaneous
Prevention of herpes zoster, Prevention of herpes zoster-related postherpetic neuralgia
Adult: Each 0.65 mL contains live, attenuated VZV Oka/Merck strain ≥19,400 PFU: ≥50 years 0.65 mL for 1 dose.
Hướng dẫn pha thuốc
Reconstitute vaccine using the total volume of the provided diluent. Agitate to mix thoroughly.
Chống chỉ định
Hypersensitivity. Immunosuppression or immuinodeficiency (e.g. HIV infection, leukaemia, lymphoma or other malignant neoplasms, history of primary or acquired immunodeficiency states), active infection (e.g. untreated TB). Pregnancy and lactation.
Thận trọng
Patient with mild acute illness with or without low grade fever, personal or family history of febrile convulsions.
Phản ứng phụ
Significant: Syncope.
Blood and lymphatic system disorders: Lymphadenopathy.
Ear and labyrinth disorders: Otitis.
Eye disorders: Conjunctivitis.
Gastrointestinal disorders: Abdominal pain, anorexia, aphthous stomatitis, constipation, diarrhea, nausea, vomiting.
General disorders and administration site conditions: Fatigue, fever, irritability, chills, malaise; injection site reactions (e.g. erythema, bruising, haematoma, swelling).
Musculoskeletal and connective tissue disorders: Neck stiffness, arthralgia, myalgia.
Nervous system disorders: Headache.
Psychiatric disorders: Somnolence.
Reproductive system and breast disorders: Herpes labialis.
Respiratory, thoracic and mediastinal disorders: Cough, rhinitis, respiratory tract disease, pharyngitis.
Skin and subcutaneous tissue disorders: Varicella-like rashes, contact dermatitis, pruritus.
Potentially Fatal:  Severe hypersensitivity reactions (e.g. anaphylaxis).
MonitoringParameters
Monitor for rash, fever, anaphylaxis and syncope for 15 minutes following administration.
Tương tác
Reduced immune response or risk of generalised infection when used concomitantly with immunosuppressants (e.g. corticosteroids). Concomitant treatment with salicylates (e.g. aspirin) may lead to Reye’s syndrome.
Lab Interference
May interfere with tuberculin tests.
Tác dụng
Description: Varicella-zoster virus vaccine promotes immunity to varicella by inducing both cell mediated and humoral immune responses to varicella-zoster virus (VZV). It also provides strong protection against herpes zoster and herpes-zoster-related post-herpetic neuralgia (PHN) in older patients (≥50 years) by eliciting an immune response to VZV.
Onset: Seroconversion: Approx 4-6 weeks.
Duration: 10 years.
Bảo quản
Store between 2-8°C. Do not freeze. Protect from light.
Phân loại ATC
J07BK - Varicella zoster vaccines ; Used for active immunizations.
References
Anon. Varicella Virus Vaccine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/07/2018.

Buckingham R (ed). Varicella-Zoster Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/07/2018.

Joint Formulary Committee. Varicella-Zoster Vaccines. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/07/2018.

Varivax Injection, Powder, Lyophilized, for Suspension (Merck Sharp & Dohme Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/07/2018.

Zostavax (Merck Sharp & Dohme Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 19/07/2018.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Vaccine, varicella-zoster từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Okavax
  • Varivax
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in